Scientific Online Resource System

Heart - Lung (Varna)

Atrial Fibrillation in Cancer Patients

Antoniya Kisheva, Lilyana Mircheva

Abstract

Cardiac arrhythmias are a common problem facing cancer patients and, when present, can affect quality of life and complicate the treatment of their malignancies. Recent study shows that new-onset atrial fibrillation (AF) is a sig- nificant risk factor for the subsequent diagnosis of incident cancer. AF has been found to occur with an increased fre- quency in patients with malignancies, particularly in those undergoing cancer surgery. Our data shows that 6 % of tne patients, hospitalized for paroxysmal or persistent AF are with cancer. AF in a cancer patient may be a comorbid- ity, may be а consequence of the cancer or a complication of cancer therapy. Cancer is a prothrombotic state, it is not incorporated in the risk prediction scores and some antican- cer agents act prothrombotic. At the same time some malig- nancies are associated with increased risk of hemorrhagia. There are no specific guidelines for AF management in can- cer patients. Treatment is based on general recommenda- tions from current guidelines in noncancer patients and the existing evidence in cancer patients, but there is a need of an individualized approach from a multidisciplinary team.

Keywords

atrial fibrillation, cancer

Full Text


References

Camm AJ, Kirchof P, Lip GY, Schotten U, Savelieva I et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19)2369-2429.

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719–2747.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016; 37(38):2893–2962,

https://doi.org/10.1093/eurheartj/ehw210

Rahman F, Ko D, Benjamin E. Association of Atrial Fibrillation and Cancer, JAMA Cardiol, 2016; 1(4): 384-386, doi:10.1001/jamacardio.2016.0280

Farmakis D, Parissis J, Filippatos G. Atrial Fibrillation in Cancer, JACC, Vol. 63, No. 10, 2014

Asnani A, Manning A, Mansour M, Ruskin J et al.

Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology, 2017; 3:2

Müller AD, Sonnenberg A,Wasserman IH. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci. 1994;39(11):2480-2484

Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK,Weiss NS, Sшrensen HT. Atrial fibrillation as a marker of occult cancer. PLoS One. 2014;9(8):e102861

Conen D,Wong JA, Sandhu RK, et al. Risk of malignant cancer among women with new-onset atrial fibrillation, JAMA Cardiol. 2016; 1(4):389-96 doi:10.1001/jamacardio.2016.0280

Velagapudi P, Turagam MK, Kocheril AG. Atrial fibrillation in cancer patients: an underrecognized condition. South Med J 2011;104:667–8

Guzzetti S, Costantino G, Fundarò C. Systemic inflammation, atrial fibrillation, and cancer. Circulation 2002;106:e40.

Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial аrrhythmias. Circulation 2001;104: 2886–91

Cardinale D, Colombo A, Sandri MT, et al. Increased postoperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer. Circulation 2007;115:1339–44

Nojiri T, Maeda H, Takeuchi Y, et al. Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 2010;140:764–8

Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34:1102–11.

Lee AY. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 2005;51:150–7

Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–83.

Riber LP, Christensen TD, Jensen HK, Hoejsgaard A, Pilegaard HK. Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg 2012; 94:339–44




DOI: http://dx.doi.org/10.14748/hl.v23i0.5896

Refbacks

Font Size


|